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As a result of the high rate of infection, the NKF-K/DOQI
guidelines recommended that an uncuffed catheter (UC)
should not be used for longer than 3 weeks. However, the
findings of the Dialysis Outcomes and Practice Patterns Study
recognized that 48% of new hemodialysis patients in the US
and 75% in Europe used UC for temporary access during
arteriovenous fistula or graft maturation. The antibiotic lock
technique (ALT) has been recommended to prevent
catheter-related bacteremia (CRB). Here, we prospectively
evaluated the efficacy of catheter-restricted filling using an
antibiotic lock solution in preventing CRB. A total of 120 new
hemodialysis patients requiring a temporary catheter while
waiting for placement and maturation of an arteriovenous
fistula or graft were enrolled in this study. Patients with a UC
were randomly assigned to receive either an antibiotic–
heparin lock solution (antibiotic group: cefazolin 10 mg/ml,
gentamicin 5 mg/ml, heparin 1000 U/ml) or a heparin lock
solution (no-antibiotic group: heparin 1000 U/ml) as a catheter
lock solution during the interdialytic period. The end point of
the trial was CRB. CRB developed in seven (11.7%) patients in
the no-antibiotic group (Staphylococcus aureus, two;
Staphylococcus epidermidis, five) whereas only one patient in
the antibiotic group had S. aureus bacteremia. CRB rates per
1000 catheter-days were 0.44 in the antibiotic group versus
3.12 in the no-antibiotic group (P¼ 0.031). Kaplan–Meier
analysis also showed that mean CRB-free catheter survival of 59
days (95% CI, 58–61 days) in the antibiotic group was greater
than that in the no-antibiotic group (55 days; 95% CI, 50–59
days). The results suggest that ALT may be a beneficial means
of reducing the CRB rate in hemodialysis patients with UC.
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Of the various complications related to hemodialysis
catheters, catheter-related infection has a significant negative
impact. It increases patient morbidity and mortality, and
medical costs. In particular, catheter-related bacteremia
(CRB) is a severe complication that requires hospitalization,
systemic antibiotic therapy, and removal, re-insertion, or
replacement of catheters.1
Although the incidence of CRB is found to differ according
to the investigator, the incidence of CRB was found to be
higher for an uncuffed catheter (UC) at 3.8–12.8 events per
1000 catheter-days2–4 than a tunnelled cuffed catheter (TCC) at
0.5–5.5 events per 1000 catheter-days.5–9 In terms of the
incidence of CRB by site of catheter insertion, the incidence of
bacteremia exceeded 10% one week after UC insertion into the
femoral vein and after three weeks for the internal jugular
vein.3 Therefore, the NKF-K/DOQI guidelines recommended
TCC as a temporary hemodialysis catheter during the
arteriovenous fistula or graft maturation period.10,11
However, TCC insertion is associated with disadvantages
such as medical expense, post-catheter placement pain, the
need for expert manpower, a fluoroscopic monitoring facility,
and a protracted operation time. Thus, it is common practice
to use a UC for three or more weeks despite the increased risk
of infection.12 A single Korean institutional study by Kim
et al.13 reported that 67% of new end-stage renal disease
(ESRD) patients received catheter-based dialysis therapy and
of them, 69% used a UC for more than three weeks.
According to the Dialysis Outcomes and Practice Patterns
Study (DOPPS), the percentage of patients with a UC among
total hemodialysis catheter patients was 48% in the United
States and 75% in Europe.12
Vascular access for hemodialysis is easily provided by
catheters, but the high risk of catheter-related infection has a
significant adverse effect on the clinical course of ESRD
patients. In an attempt to prevent infection, the antibiotic
lock technique (ALT) was introduced to prevent intraluminal
spread by microorganisms that can occur through the
catheter hub. However, previous studies have focused on
TCC only.1,14
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In this study, we evaluated the ability of ALT to reduce UC
infection rates, because UCs are frequently used as a means of
temporary vascular access despite their well-known high rate
of infection.
RESULTS
Baseline characteristics of patients
The clinical and biochemical characteristics of patients in the
antibiotic group and the no-antibiotic group are shown in
Table 1. No statistically significant differences were found
between the two groups in terms of age, sex, underlying
diabetic nephropathy, hemoglobin, serum ferritin, serum
albumin, and duration of catheterization.
Comparison of the rates of catheter-related bacteremia
The incidence of CRB was significantly lower in the antibiotic
group (P¼ 0.031); CRB rates per 1000 catheter-days were 0.44
events in the antibiotic group versus 3.12 events in the no-
antibiotic group. CRB developed in seven patients (11.7%) in
the no-antibiotic group but in only one patient (1.7%) in the
antibiotic group. All causative organisms were Gram-positive:
one case of Staphylococcus aureus in the antibiotic group, two
cases of S. aureus, and five cases of Staphylococcus epidermidis
in the no-antibiotic group, and all Staphylococci were
methicilin-sensitive strains (Tables 2 and 3).
Analysis of cumulative infection-free catheter survival
Cumulative infection-free catheter survival was significantly
higher in the antibiotic group than in the no-antibiotic group
(log-rank statistic, 4.66; P¼ 0.031) (Figure 1).
DISCUSSION
Given the current situation whereby UCs are commonly used
as a means of temporary vascular access until arteriovenous
fistula or graft maturation, we undertook this study to
determine whether the use of ALT for hemodialysis patients
with UC could provide an effective low-cost alternative
means of reducing the CRB rate.
Before introducing ALT in the dialysis unit, only 12
patients (4.8%) had started dialysis with arteriovenous fistula
or graft, or had received a TCC insertion for temporary or
permanent vascular access. Thus, most of the new hemodia-
lysis patients in our dialysis unit used a UC and were thus
exposed to a greater risk of infection. In the present study, the
control group (no-antibiotic group) showed an 11.7%
incidence of CRB (3.12 events per 1000 catheter-days),
which was similar to the incidences of CRB in previous UC
studies. However, the application of ALT resulted in a
considerable reduction in CRB rate (0.44 events per 1000
catheter-days). This result is consistent with that of a
comparative study by Dogra et al.,15 who showed the
preventive effect of a gentamicin–citrate mixture on the
incidence of CRB in patients with TCC, and also with that of
a study by McIntyre et al.,16 who compared the use of a
gentamicin–heparin mixture with heparin only.
Many investigators have selected gentamicin as an
antibiotic for preventive purposes, but available data of
Table 1 | Characteristics of patients
Characteristics
Antibiotic
group
No-antibiotic
group P-value
Age (years) 53.68715.201 56.18715.684 NS
Sex (male) (n (%)) 33 (55.0) 28 (46.7) NS
DM (n (%)) 30 (50.0) 33 (55.0) NS
Hemoglobin (g/dl) 8.8071.14 9.0371.07 NS
Ferritin (mg/l) 392.1748.2 403.8758.5 NS
Albumin (g/dl) 3.4770.66 3.3570.58 NS
Duration of catheterization
Mean (days) 37.6876.44 37.3775.59 NS
Median (range) (days) 36.50 (28–60) 35.50 (28–61) NS
The % of catheter
use 430 days
88.3 96.7 NS
Data are means7s.d.
DM: diabetes mellitus; NS: not statistically significant.
Table 2 | Incidence of CRB
Total
(n=120)
Antibiotic
group (n=60)
No-antibiotic
group (n=60) P-value
No. of patients (n, %) 8 (6.7) 1 (1.7) 7 (11.7)
CRB rates per 1000
catheter-days
0.44 3.12 0.031
Mean CRB-free
catheter survival (days)
59
(95% CI, 58–61)
55
(95% CI, 50–59)
CRB: catheter-related bacteremia; CI: confidence interval.
Duration of catheterization 
(days)
Antibiotic
group
No-antibiotic
group
Log-rank statistic, 4.66 
P = 0.031
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Figure 1 | Comparison of percentage of patients free of CRB.
Table 3 | CRB patients
Patient Days to CRB Organism
Antibiotic group M/51 DM 35 S. aureus
No-antibiotic group F/31 Non-DM 36 S. epidermidis
F/51 Non-DM 34 S. epidermidis
M/48 Non-DM 28 S. aureus
F/43 DM 31 S. epidermidis
M/43 Non-DM 42 S. epidermidis
F/56 DM 44 S. epidermidis
M/35 Non-DM 37 S. aureus
CRB: catheter-related bacteremia; M: male; F: female; DM: diabetes mellitus.
All Staphylococci were methicilin-sensitive strains.
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gentamicin lock solutions are relatively limited, and cannot
be easily compared because of the different concentrations of
gentamicin and citrate used in various studies. Andris et al.17
suggested the possibility of using various types of antibiotics
in ALT in the total parenteral nutrition catheter model,
but there have been no studies comparing the effect of
various types of antibiotic on reducing CRB. Therefore,
the optimal drug regimen and concentrations for ALT need
to be defined.14
Currently, vancomycin-resistant enterococcus has become a
problem, especially in hemodialysis patients owing to the
widespread use of vancomycin as empiric or first-line therapy,18
but the single use of cefazolin or concurrent cefazolin–genta-
micin administration is found to be the empiric antibiotic
of choice in a dialysis unit with a low methicillin-resistant
S. aureus infection rate.19,20 Based on these study results, we
selected cefazoline as an antibiotic for ALT.
In an in vitro hemodialysis catheter study by Vercaigne
et al.,21 it was found that a combination antibiotic–heparin
lock had a higher sterilization effect on methicillin-resistant
S. epidermidis than a single antibiotic–heparin lock. They also
found that a vancomycin–gentamicin–heparin lock solution
(VGH lock) and a cefazolin–gentamicin–heparin lock solu-
tion (CGH lock) showed similar bactericidal effects. Accord-
ingly, in the present study, a combination antibiotic lock was
adopted by combining cefazolin (empiric antibiotic to Gram-
positive organisms) and gentamicin (empiric antibiotic to
Gram-negative organisms).
Citrate, which has been used as an anticoagulant in
catheter lock solutions in ALT, has little antimicrobial effect
at concentrations of 2% or lower, and has an antimicrobial
effect at concentrations of 30% or higher owing to
hyperosmolality. However, it is known to show an anti-
microbial effect in its mid-concentration (2.2–15%) range to
Gram-positive microorganisms. Thus, there is a possibility
that citrate has an additive antimicrobial effect in ALT.22,23
But citrate is also known to induce cardiac dysfunction24 and
is relatively expensive compared to heparin, which has been
reported to be stable in an antibiotic–heparin mixture form
for a prolonged period (72 h);21 hence, we chose heparin as
an anticoagulant.
No catheter malfunction was found in the present study in
relation to the application of ALT and this may be due to the
relatively short-term use of less than two months. McIntyre
et al.16 also reported no difference in catheter functions
between the ALT group and heparin groups.
There was no experience of adverse reaction due to
aminoglycoside ototoxicity or cephalosporin CNS toxicity
in all patients of the ALT group. As no adverse events
associated with ALT may be due to the short-term use of ALT,
lower antibiotic concentrations, and small number of
patients in our dialysis unit, further studies are needed in
this area.
This study has several limitations. Although there was no
adverse reaction due to aminoglycoside ototoxicity or
cephalosporin CNS toxicity, drug level monitoring to identify
systemic exposure to antibiotics such as cefazolin and
gentamicin was not carried out in this study. Cefazolin is
known not to have adverse CNS effects when administered
three times a week,20 and is not considered to cause a
problem because antibiotics act in the lumen of catheters
and, even in the case of leakage, antibiotics were present at
low dose. In the case of gentamicin, about 10% of patients
complained of symptoms compatible with aminoglycoside
ototoxicity when TCC had been used for long periods at
high dosages (ca. 40 mg/ml).15 This warrants the study
of the efficacy of lower gentamicin concentrations. Because
plasma levels of both antibiotics were not measured and
this study was conducted at a single medical center, these
may limit the generalization of the results from this
study, preventing CRB. Additional studies are needed to
confirm the suitability of antibiotic mixture of this
study protocol. Also, ALT was applied to patients using
UCs for longer than 1 month in this study. Therefore,
the data suggest that ALT is only needed when catheters
are in place for a period longer than 1 month. This means
a clear restriction for the usefulness of this approach.
Additional studies are needed to evaluate the usefulness
of short-term application of ALT to UCs used for less
than 1 month.
ALT in patients using UC may be a low-cost means of
reducing the incidence of CRB in patients in whom it is
practically difficult to place a TCC for temporary vascular
access during arteriovenous fistula or graft maturation.
But widespread use of ALT may not be ideal because of the
selection for antibiotic-resistant organisms. A recent study
comparing taurolidine lock with standard heparin lock
reported effective reduction of CRB.25,26 Taurolidine is not
an antibiotic but has a broad range of antimicrobial activity,
and bacterial resistance has not been observed.27,28 Thus,
taurolidine-containing catheter lock solution may be an
alternative strategy for preventing emergence of antibiotic-
resistant bacteria.
CONCLUSION
This study suggests that ALT may be a beneficial means of
reducing CRB in UC for temporary vascular access during
arteriovenous fistula or graft maturation. Further studies are
required to determine the optimal drug regimen and
concentrations for ALT.
MATERIALS AND METHODS
Study design and patients
Between March 2001 and February 2003, 120 new ESRD patients (61
male and 59 female patients) requiring a temporary catheter while
waiting for placement and maturation of an arteriovenous fistula or
graft at the Nephrology Department of GangNeung Asan Hospital,
University of Ulsan College of Medicine, were enrolled. Patients who
already had an infection or who were under antibiotic therapy were
excluded.
All patients gave informed consent and randomly assigned to
either an antibiotic group or a no-antibiotic group. The antibiotic
group (ALT group) was prescribed antibiotic–heparin lock solution
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as a catheter lock solution during the interdialytic period. This was a
mixture of 10 mg/ml cefazolin, 5 mg/ml gentamicin, and 1000 U/ml
heparin. Members of the ‘no-antibiotic’ group (control group) were
prescribed with a solution containing heparin-only, as is common in
dialysis units. Block randomization was made using table of random
numbers. Study blinding was accomplished by ensuring that neither
subjects nor dialysis nurses knew which catheter lock solutions were
instilled. The study investigator who assessed outcomes and the staff
who were involved in the preparation of catheter lock solution were
not blinded. The end point of the trial was CRB. Incidences of CRB
in the two groups were compared. CRB was defined as the isolation
of the same organism from a semiquantitative culture of the catheter
tip (415 colony-forming units), a peripheral blood sample, and a
catheter blood sample. An intervention radiologist inserted UCs
(Mahurkar dual lumen catheter with curved extension, Quinton,
USA) into the right internal jugular vein under ultrasound and
fluoroscopic guidance. Inserted catheters were managed using
infection prophylaxis protocols in accordance with the NKF-K/
DOQI guidelines.10
Statistical analyses
All analyses were performed on an intention-to-treat basis. Data
are represented as means7standard deviations or as medians and
ranges. The Student’s t-test, Mann–Whitney U-test, and w2 test
were used to compare patient characteristics. CRB rates (CRB events
for 1000 catheter-days) were compared using the log-rank test.
Cumulative infection-free catheter survivals were determined
using the Kaplan–Meier method and compared using the log-rank
test. P-values o0.05 were considered statistically significant.
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